Cancer Drug Resistance JCR impact factor overview
Automatically generated from the journal record shown on this page.
Clarivate JCR impact factor overview
Cancer Drug Resistance is listed in this directory with bibliometric information for 2025. It is published by OAE PUBLISHING INC. The database records a Journal Impact Factor of 5.200, presented as a Clarivate Journal Citation Reports (JCR)-based metric. Its listed JCR Impact Factor quartile is Q1.
Ranking and quartile
The recorded JCR Impact Factor category rank is 64 out of 326 journals in its listed category. A Q1 designation describes the journal’s position within its subject category; it should not be used as a direct measure of the quality of an individual article.
Citation profile
The record contains 1,828 total citations, 21 total articles, 54 citable items. The five-year Impact Factor is 5.300, which is 0.100 points above the listed standard Journal Impact Factor. These values use different citation windows and should be interpreted together rather than as a direct trend. The Journal Impact Factor without journal self-citations is recorded as 5.100. The Journal Citation Indicator is listed as 0.760.
Citation half-life
The cited half-life is recorded as 3.8 years, describing the median age of articles cited in the reporting year. The citing half-life is 5.4 years, reflecting the median age of references used by the journal’s articles.
Journal identifiers and verification
Cancer Drug Resistance is identified in this record by electronic ISSN 2578-532X. Use the ISSN when checking library catalogues, publisher records, indexing databases, or the official Clarivate Journal Citation Reports entry.
Complete journal information
All values below come directly from the database record.
| Journal name | Cancer Drug Resistance |
|---|---|
| Abbreviated journal | CANCER DRUG RESIST |
| Publisher | OAE PUBLISHING INC |
| Metric year | 2025 |
| Overall rank | 1,901 |
| ISSN | Not available |
| eISSN | 2578-532X |
| Total cites | 1,828 |
| Total articles | 21 |
| Citable items | 54 |
| Cited half-life | 3.8 years |
| Citing half-life | 5.4 years |
| JCR-based Journal Impact Factor | 5.200 |
| 5-Year Impact Factor | 5.300 |
| Impact Factor without journal self-cites | 5.100 |
| Journal Citation Indicator | 0.760 |
| JCR Impact Factor quartile | Q1 |
| JCR category rank | 64/326 |
| Database record updated |
Frequently asked questions
What is the 2025 JCR-based Journal Impact Factor of Cancer Drug Resistance?
The Journal Impact Factor recorded in this directory as a Clarivate Journal Citation Reports (JCR)-based value for Cancer Drug Resistance is 5.200 for the 2025 metric year.
What quartile is Cancer Drug Resistance?
Cancer Drug Resistance is listed in quartile Q1. Quartiles describe a journal’s position within a subject category and should be interpreted within that field.
Who publishes Cancer Drug Resistance?
Cancer Drug Resistance is listed as being published by OAE PUBLISHING INC.
Can a JCR Journal Impact Factor be used to judge an individual article?
No. The Journal Impact Factor is a journal-level citation measure reported in Clarivate Journal Citation Reports. It does not measure the quality, reliability or influence of every individual article published by that journal.
Related journal profiles
Additional records from the same publisher or with a similar listed JCR Impact Factor.